Alterations in NO production and bioavailability [3,4], sGC activation and stimulation [5,6], and cGMP signaling [7] have been implicated in the pathogenesis of atherosclerosis, heart failure, and kidney disease. The gene discussed is SGCB; the disease is atherosclerosis.